CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues
Revenues	$ 2,138	$ 2,209	$ 5,814	$ 6,377
Expenses
Selling, general and administrative	572	648	1,731	1,886
Research and development	103	123	333	357
Amortization of intangible assets	391	475	1,263	1,452
Asset impairments	2	33	17	49
Restructuring, integration and separation costs	2	4	13	28
Acquisition-related contingent consideration	2	3	26	2
Other expense, net	16	10	146	15
Total expenses	1,678	1,880	5,133	5,504
Operating income	460	329	681	873
Interest income	2	2	11	9
Interest expense	(374)	(406)	(1,155)	(1,221)
Loss on extinguishment of debt	0	0	(51)	(40)
Foreign exchange and other	(13)	9	(26)	12
Income (loss) before (provision for) benefit from income taxes	75	(66)	(540)	(367)
(Provision for) benefit from income taxes	(5)	18	133	101
Net income (loss)	70	(48)	(407)	(266)
Net loss (income) attributable to noncontrolling interest	1	(1)	0	(6)
Net income (loss) attributable to Bausch Health Companies Inc.	$ 71	$ (49)	$ (407)	$ (272)
Earnings (loss) per share attributable to Bausch Health Companies Inc.
Basic (in usd per share)	$ 0.20	$ (0.14)	$ (1.15)	$ (0.77)
Diluted (in usd per share)	$ 0.20	$ (0.14)	$ (1.15)	$ (0.77)
Weighted-average common shares
Basic (in shares)	355.6	352.4	354.7	351.9
Diluted (in shares)	357.8	352.4	354.7	351.9
Product sales
Revenues
Revenues	$ 2,111	$ 2,180	$ 5,734	$ 6,291
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	578	571	1,565	1,675
Other revenues
Revenues
Revenues	27	29	80	86
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 12	$ 13	$ 39	$ 40